Merckle GmbH
🇩🇪Germany
Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 49
- Registration Number
- NCT02592031
PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT02306915
- Locations
- 🇬🇧
Teva Investigational Site 34193, London, United Kingdom
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Phase 1
Completed
- Conditions
- Ewing Family of Tumors, Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Merckle GmbH
- Target Recruit Count
- 21
- Registration Number
- NCT01585649
- Locations
- 🇧🇬
Teva Investigational Site 0103, Plovdiv, Bulgaria
🇧🇬Teva Investigational Site 0102, Varna, Bulgaria
🇺🇦Teva Investigational Site 0704, Kyiv, Ukraine
© Copyright 2025. All Rights Reserved by MedPath